Treatment appraisals – the process explained Fast Track - access to treatments

Across England, treatments are reviewed through National Institute for Health and Care Excellence (NICE) processes. Wales and Northern Ireland tend to also follow NICE’s decision making. However, in Scotland, the Scottish Medicines Consortium (SMC) is responsible for appraising new treatments.

With more neuromuscular treatments going through NICE, MDUK has been busier than ever engaging with both NICE and the SMC to ensure people living with a muscle-wasting condition across the UK access new treatments as soon as possible. This entails multiple steps and means we need to work closely with these organisations, in addition to pharmaceutical companies, and other patient representative charities and the MDUK community throughout each appraisal.

With more attention than ever in the community on new treatments on the horizon, we appreciate it can be confusing to understand the process and how the patient voice is represented in treatment appraisals. If you would like to understand more about the NICE appraisal process, please read our explainer here

Similarly, we have created an explained for the SMC appraisal process for those living in Scotland (see here)